| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Lisitinib | GDSC1000 | pan-cancer | AAC | 0.0051 | 0.9 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | 0.0054 | 0.9 |
| mRNA | SNX-2112 | GDSC1000 | pan-cancer | AAC | 0.0044 | 0.9 |
| mRNA | fingolimod | CTRPv2 | pan-cancer | AAC | -0.0053 | 0.9 |
| mRNA | vincristine | CTRPv2 | pan-cancer | AAC | 0.0045 | 0.9 |
| mRNA | BRD-K66453893 | CTRPv2 | pan-cancer | AAC | 0.0046 | 0.9 |
| mRNA | Cisplatin | GDSC1000 | pan-cancer | AAC | -0.0049 | 0.9 |
| mRNA | Bortezomib | FIMM | pan-cancer | AAC | -0.022 | 0.9 |
| mRNA | docetaxel:tanespimycin (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0044 | 0.9 |
| mRNA | BRD-A86708339 | CTRPv2 | pan-cancer | AAC | -0.0067 | 0.9 |